HTD · Financial Services
Corcept Therapeutics Inc
33/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
44
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$904M
Industry
Asset Management
Sector
Financial Services
Exchange
NYSE
About CORCEPT THERAPEUTICS INC
John Hancock Tax-Advantaged Dividend Income Fund is a closed ended equity mutual fund launched and managed by John Hancock Investment Management LLC. It is co-managed by John Hancock Asset Management and Analytic Investors, LLC. The fund invests in the public equity markets of the United States. It seeks to invest in stocks of companies operating across diversified sectors, with an emphasis on the utilities sector. The fund primarily invests in dividend-paying common and preferred stocks of companies which have dividends that qualify for a more favorable long-term capital gains tax rate. It…
Who's behind the signal
Every informed buyer we can see on HTD, across all three feeds.
Hedge funds · 8
Point72 (Steve Cohen)
New position
D.E. Shaw & Co
Increased +596%
Millennium Management (Englander)
Increased +532%
Tudor Investment (Paul Tudor Jones)
Increased +267%
Gotham Asset Mgmt (Greenblatt)
Increased +3%
Bridgewater Associates (Dalio)
Decreased −86%
+2 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
CORCEPT THERAPEUTICS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
1
New positions
4
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+596%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+532%
0.0% of Millennium Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
+267%
0.0% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+3%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
−86%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−70%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−54%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to CORCEPT THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell CORCEPT THERAPEUTICS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订